Clinical Trial Update: A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 multiple-dose study of ABT-288 in stable subjects with schizophrenia to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ABT-288 (ABT-288)

Snippet

Sponsor: AbbVie | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED